Introduction and Situational Analysis Merck and River Blindness ethical dilemma is whether to pursue research that may or may affect the profits‚ or to choose a safer choice and go for profit rather than researching the drug. The outcome from researching the drug could possibly lead to healing the deadly and dangerous disease known as River Blindness. This drug is known to kill the parasite that has caused the disease. The problem with this situation was that the consumers of the drug could not pay
Premium Pharmacology Medicine Ethics
Table of Contents Section 1…………………………………………………………………………………3 Section 2…………………………………………………………………………………4 Section 3…………………………………………………………………………………6 Section 4…………………………………………………………………………………9 Section 1: Introduction and Situational Analysis Onchocerciasis‚ known as river blindness‚ is caused by parasitic worms that live in the small black flies that breed in and about fast-moving rivers in developing countries in the Middle East‚ Africa‚ and Latin America. The disease‚ if untreated causes
Premium Ethics Decision making Onchocerciasis
MERCK: OPEN FOR INNOVATION? Founded in 1891 as an American subsidiary of his German namesake‚ Merck was once considered the “undisputed king of the pharmaceutical industry with ground‐ breaking drugs”(The Chief Executive 2003). But for the last decade‚ Merck has gone through a period of stagnation; it began to lose exclusivity patents on blockbuster drugs and has witnessed Pfizer’s rise to top place in the industry. It seemed now that internal R&D that was once the company’s main asset would
Premium Pharmaceutical industry
Merck‚ being on one of the biggest pharmaceutical companies in the world today‚ came from a meek beginning and still encounters many problems today while trying to maintain a lead amongst its competition. While being looked at as a research and development driven company‚ Merck now has to go beyond R&D to stay competitive in the pharmaceutical industry. Attracting talent to work for the company has never been a problem for Merck‚ but the bigger question was whether or not this talent would be able
Premium Pharmaceutical industry Pharmacology Generic drug
EXECUTIVE SUMMARY Statement of the Problem Merck & Co.‚ Inc.‚ a leading pharmaceutical company‚ faces the threat of the patents of its most popular drugs expiring in 2002. The only way to counter the loss of sales from these drugs going off patent is to develop new drugs in order to refresh the company’s portfolio. LAB Pharmaceuticals‚ a small pharmaceutical company who specializes in the treatment of neurological disorders‚ has approached Merck with the opportunity to license Davanrik‚ a new
Premium Patent Pharmacology Pharmaceutical drug
Case Memo: Merck Global Health and Access to Medicines The topic‚ human rights responsibilities of the drug companies‚ which is always controversial‚ however‚ is almost sharply defined in a report by the UN Special Rapporteur on the right to health‚ submitted to the United Nations General Assembly in August 2008. 1 The ‘‘Human Rights Guidelines for Pharmaceutical Companies in relation to Access to Medicines’’ include responsibilities for transparency‚ management‚ monitoring and accountability
Premium Human rights Costs Clinical trial
Merck Acquisition of Medco Case Study John X Devry University – Keller Graduate School of Management Finance 561 Professor May 22‚ 2011 Table of Contents Abstract………………………………………………………………………………………p.g. 3 Company backgrounds……………………………………………………….………………p.g. 3 Merck & Co.‚ Inc. ………………………………………..…………………….…....p.g. 3 Medco Containment Services Inc. ............................……..…………………………p.g. 4 Reasons for Mergers…………………………………………………………………………p.g. 5 Economies of Scale………………………………………………………………….
Premium Mergers and acquisitions Marketing
Merck‚ Vioxx and the FDA Recall‚ case no. 6 1. I believe that Merck was completely responsible for everything that came along with releasing Vioxx to the public. The signs that the drug might not be as safe as they had hoped for should have been enough for them to halt on the release. It was unethical thing they did was not do all the research to find out how serious the effects of the drug really were. 2. Merck should have run more tests and found out the severity of the symptoms‚ and seen
Free Pharmacology Food and Drug Administration
CEO Ray Gilmartin Merck’s CEO Ray Gilmartin is a significant stakeholder in the company. Since a lot of Mercks’ products patents will be expiring in the next few years Gilmartin put a big emphasis on investing into the companies research and development of new products. Gilmartin wanted this company to really focus on coming out with new products because their bottom line was going to take a hit in the next few years once the patent on their big money products runs out. Gilmartin found it an
Premium Pharmacology Finance Management occupations
research scientist working for Merck and Company‚ discovered evidence that one of the company’s drugs might kill the parasite that causes river blindness. He then decided to request permission to research this new finding. The mangers for the company noticed that it would take enormous amount of funding and time to develop this new vaccine. This new product could be really hard to market and who was going to actually buy it; it could also damaged the market share that Merck currently had by selling
Premium Medicine Science Physician